Evidence map›Paper›PMID 42205536›Full record

ReviewFrontiers in molecular biosciences2026

Nanotechnology for ischemic stroke treatment: addressing challenges across stroke management stages.

Yue Wu, Lijun Wang, Chen Zou, Xianfu Meng, Pengfei Yang, Hongjian Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yue Wu *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Lijun Wang *Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Chen Zou *School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Xianfu MengDepartment of Nuclear Medicine, Shanghai Key Laboratory of Nautical Medicine and Translation of Drugs and Medical Devices, Changhai Hospital, Naval Medical University, Shanghai, China.
Pengfei YangOriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China.
Hongjian ZhangOriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke is a leading cause of mortality and long-term disability, with single acute interventions such as thrombolysis and mechanical thrombectomy limited by narrow therapeutic windows, hemorrhage risks, and challenges in crossing the blood-brain barrier (BBB). This review focuses on targeted therapeutic strategies across the four key stages of ischemic stroke management: prevention, neuroprotection, revascularization, and adjunctive therapy. By systematically analyzing each stage of ischemic stroke, we emphasize the necessity of staged intervention and the essential role of nanomedicines during each stage. From controlled drug release in the prevention stage to the extension of therapeutic time windows for acute intervention and to enhancing adjunctive outcomes in later stages, nanomedicines provide solutions to optimize treatment efficacy and minimize side effects. Finally, we provide perspectives on spatiotemporal control in nanomedicine for precision stroke treatment, including blood pressure and infarct temperature regulation, the crosstalk between systems, and gene therapy. This review underscores the transformative role of nanomedicines in ischemic stroke treatment and the potential to revolutionize stroke management by overcoming current clinical barriers and improving patient outcomes.

Indexed as

cerebral ischemiaischemic strokenanomedicines for ischemic stroke treatmentstaged interventionstroke management stage

Identifiers

PMID42205536
PMCPMC13201122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.